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the drug. A dermatitis necessitating withdrawal of the drug has been described (Hollander et al. 1960 , Oaks 1960 and 2 patients in this trial had transient skin disorders. A more serious dermatitis complicated by hair changes and cataract in 4 patients on normal doses of MER-29 has recently been reported (Mansell-Jones 1962, personal communication) . Two patients complained of loss of scalp hair which has been described, and so, surprisingly, has re-growth (Toro 1960) . Diminished libido has been reported (Kountz 1960) and this occurred in one of the male patients. Nausea and constipation were frequent complaints, though not necessitating withdrawal of the drug unless the dose was high (Hollander et al. 1960 , Oaks 1960 . Other toxic effects reported have been leucopenia (Oaks 1960) , reduction of urinary corticosteroid excretion (Hollander & Chobanian 1959) and temporary post-menopausal bleeding (Toro 1960) , but none of these has been observed in this trial.
Summary and Conclusions
Fifteen patients with hypercholesterolhmia and ischemic heart disease or xanthomatosis were treated with MER-29 (triparanol) for periods of between two and fifteen months. Four patients developed a myocardial infarct and in 3 this was fatal. There was no evidence of any improvement in angina, and the drug was discontinued in 2 patients, because of increase in this symptom. No significant diminution of xanthomata was found.
Minor toxic effects occurred, with elevation of alkaline phosphatase in 4 patients. Serious skin changes with cataract formation were not observed.
The apparent serum cholesterol, as measured by the Leibermann-Burchard reaction, was reduced by only 160% on treatment. This implies an even smaller reduction of total sterol, due to the accumulation of demosterol in the serum. The apparent cholesterol rose in-2 patients with xanthomatosis who died of myocardial infarction.
It is concluded that MER-29 is not suitable for the general treatment of ischkmic heart disease or xanthomatosis until the atherogenic properties of desmosterol are known.1
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